Top

Published in:

Open Access 01-12-2012 | Research article

REGγ is associated with multiple oncogenic pathways in human cancers

Authors: Jing He, Long Cui, Yu Zeng, Guangqiang Wang, Ping Zhou, Yuanyuan Yang, Lei Ji, Yanyan Zhao, Jiwu Chen, Zhuo Wang, Tieliu Shi, Pei Zhang, Rui Chen, Xiaotao Li

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

Recent studies suggest a role of the proteasome activator, REGγ, in cancer progression. Since there are limited numbers of known REGγ targets, it is not known which cancers and pathways are associated with REGγ.

Methods

REGγ protein expressions in four different cancers were investigated by immunohistochemistry (IHC) analysis. Following NCBI Gene Expression Omnibus (GEO) database search, microarray platform validation, differential expressions of REGγ in corresponding cancers were statistically analyzed. Genes highly correlated with REGγ were defined based on Pearson's correlation coefficient. Functional links were estimated by Ingenuity Core analysis. Finally, validation was performed by RT-PCR analysis in established cancer cell lines and IHC in human colon cancer tissues

Results

Here, we demonstrate overexpression of REGγ in four different cancer types by micro-tissue array analysis. Using meta-analysis of publicly available microarray databases and biological studies, we verified elevated REGγ gene expression in the four types of cancers and identified genes significantly correlated with REGγ expression, including genes in p53, Myc pathways, and multiple other cancer-related pathways. The predicted correlations were largely consistent with quantitative RT-PCR analysis.

Conclusions

This study provides us novel insights in REGγ gene expression profiles and its link to multiple cancer-related pathways in cancers. Our results indicate potentially important pathogenic roles of REGγ in multiple cancer types and implicate REGγ as a putative cancer marker.

Available only for authorised users

Mao I, Liu J, Li X, Luo H: REGgamma, a proteasome activator and beyond. Cellular Mol Life Sci. 2008, 65: 3971-3980. 10.1007/s00018-008-8291-z.CrossRef

Okamura T, Taniguchi S, Ohkura T, Yoshida A, Shimizu H, Hisatome I, Shiqemasa C: Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. JCEM. 2003, 88: 1374-1383.PubMed

Markus R: Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by combing two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cellular Proteomics. 2006, 1: 2092-2101.

Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, et al: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007, 13: 1133-1139. 10.1158/1078-0432.CCR-06-1025.CrossRefPubMed

Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008, 13: 529-541. 10.1016/j.ccr.2008.04.019.CrossRefPubMedPubMedCentral

Hong Y, Ho KS, Eu KW, Cheah PY: A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Clin Cancer Res. 2007, 13: 1107-1114. 10.1158/1078-0432.CCR-06-1633.CrossRefPubMed

Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA: Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007, 7: 64-10.1186/1471-2407-7-64.CrossRefPubMedPubMedCentral

Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003, 9: 416-423. 10.1038/nm843.CrossRefPubMed

Okamura T, Taniguchi S, Ohkura T, Yoshida A, Shimizu H, Sakai M, Maeta H, Fukui H, Ueta Y, Hisatome I, Shigemasa C: Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J Clin Endocrinol Metab. 2003, 88: 1374-1383. 10.1210/jc.2002-021413.CrossRefPubMed

10.

Barrett T, Edgar R: Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol. 2006, 411: 352-369.CrossRefPubMedPubMedCentral

11.

Shi L, Jones WD, Jensen RV, Harris SC, Perkins RG, Goodsaid FM, Guo L, Croner LJ, Boysen C, Fang H, et al: The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics. 2008, 9 (Suppl 9): S10-10.1186/1471-2105-9-S9-S10.CrossRefPubMedPubMedCentral

12.

Maouche S, Poirier O, Godefroy T, Olaso R, Gut I, Collet JP, Montalescot G, Cambien F: Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells. BMC Genomics. 2008, 9: 302-10.1186/1471-2164-9-302.CrossRefPubMedPubMedCentral

13.

Sean D, Meltzer PS: GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007, 23: 1846-1847. 10.1093/bioinformatics/btm254.CrossRef

14.

Fox RJ, Dimmic MW: A two-sample Bayesian t-test for microarray data. BMC Bioinformatics. 2006, 7: 126-10.1186/1471-2105-7-126.CrossRefPubMedPubMedCentral

15.

Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3-PubMed

16.

Baldi P, Long AD: A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics. 2001, 17: 509-519. 10.1093/bioinformatics/17.6.509.CrossRefPubMed

17.

Mansson R, Tsapogas P, Akerlund M, Lagergren A, Gisler R, Sigvardsson M: Pearson correlation analysis of microarray data allows for the identification of genetic targets for early B-cell factor. J Biol Chem. 2004, 279: 17905-17913. 10.1074/jbc.M400589200.CrossRefPubMed

18.

Rosner B: Fundamentals of Biostatistics. 2006, Belmont, CA: Thomson-Brooks/Cole, 6

19.

Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, et al: STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009, 37: D412-416. 10.1093/nar/gkn760.CrossRefPubMed

20.

Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH, Huang CY: Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics. 2007, 8: 140-10.1186/1471-2164-8-140.CrossRefPubMedPubMedCentral

21.

Fontaine JF, Mirebeau-Prunier D, Franc B, Triau S, Rodien P, Houlgatte R, Malthiery Y, Savagner F: Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene. 2008, 27: 2228-2236. 10.1038/sj.onc.1210853.CrossRefPubMed

22.

Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC: Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One. 2009, 4: e5645-10.1371/journal.pone.0005645.CrossRefPubMedPubMedCentral

23.

Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007, 45: 938-947. 10.1002/hep.21622.CrossRefPubMed

24.

Liu J, Yu G, Zhao Y, Zhao D, Wang Y, Wang L, Li L, Zeng Y, Dang Y, Wang C, et al: REG{gamma} modulates p53 activity by regulating its cellular localization. J Cell Sci. 2010, 123: 4076-4084. 10.1242/jcs.067405.CrossRefPubMedPubMedCentral

25.

Zhang Z, Zhang R: Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 2008, 27: 852-864. 10.1038/emboj.2008.25.CrossRefPubMedPubMedCentral

26.

Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW: The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell. 2006, 124: 381-392. 10.1016/j.cell.2005.11.037.CrossRefPubMed

27.

Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, et al: A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 2007, 67: 10148-10158. 10.1158/0008-5472.CAN-07-1887.CrossRefPubMed

28.

Levine AJ, Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010, 330: 1340-1344. 10.1126/science.1193494.CrossRefPubMed

29.

Burger AM, Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 2004, 40: 2217-2229. 10.1016/j.ejca.2004.07.006.CrossRefPubMed

30.

Wellen KE, Thompson CB: Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell. 2010, 40: 323-332. 10.1016/j.molcel.2010.10.004.CrossRefPubMedPubMedCentral

31.

Yu G, Zhao Y, He J, Lonard DM, Mao CA, Wang G, Li M, Li X: Comparative analysis of REG{gamma} expression in mouse and human tissues. J Mol Cell Biol. 2010, 2: 192-198. 10.1093/jmcb/mjq009.CrossRefPubMedPubMedCentral

32.

Goh HS, Soong TW, Lee YS, Ho J, Goh CR: c-myc Oncogene expression in colorectal cancer: its use in prognosis and role in colorectal carcinogenesis. Ann Acad Med Singapore. 1990, 19: 139-141.PubMed

33.

Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson J: c-myc oncogene expression in colorectal cancer. Cancer. 1987, 59: 1289-1295. 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/75/prepub

Title: REGγ is associated with multiple oncogenic pathways in human cancers
Authors: Jing He
Long Cui
Yu Zeng
Guangqiang Wang
Ping Zhou
Yuanyuan Yang
Lei Ji
Yanyan Zhao
Jiwu Chen
Zhuo Wang
Tieliu Shi
Pei Zhang
Rui Chen
Xiaotao Li
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-75

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Development and validation of a questionnaire to assess delay in treatment for breast cancer

Expression of Bim, Noxa, and Puma in non-small cell lung cancer

Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study

Risk of tobacco-related multiple primary cancers in Bavaria, Germany

Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study

Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C

Keynote webinar | Spotlight on antibody–drug conjugates in cancer